Search

BiomX analyzed a set of colorectal cancer tumour samples from patients, and found that 80% contained Fusobacterium nucleatum, which BiomX has been engineering phages to target. BiomX's phages are designed to deliver payloads that make tumou

Adaptive Phage Therapeutics (APT) is working toward a phage-based COVID vaccine — a phage engineered to express epitopes of SARS-CoV2 on the surface of the capsid. Phage-based vaccines are attractive because they are considered safe in the

Earlier this month we posted that Adaptive Phage Therapeutics received emergency FDA authorization to treat a group of COVID-19 patients in Texas with A. baumannii infections. Now, they've received expanded access authorization to use their

Locus Biosciences signed a contract with CARB-X to advance a $14 million precision medicine program to develop their crPhage™ product, which targets Klebsiella pneumoniae infections.

Adaptive Phage Therapeutics has deployed their PhageBank™ in Texas to treat COVID-19 patients suffering from life-threatening carbapenem resistant Acinetobacter baumannii (CRAB). Eight of these patients have so far received PhageBank™ thera

BiomX has announced the dosing of their first subject in their Phase 1a clinical study testing the safety, pharmacokinetics and oral delivery of a phage therapy candidate for treatment of Inflammatory Bowel Disease. Results are expected in

Dutch phage biotech company Micreos has signed a license agreement with L'Oréal — this means L'Oréal can incorporate Micreos' phage lysins into its products, and represents a huge milestone for phage biotech making its way into the mainstre

Adaptive Phage Therapeutics (APT) has received Orphan drug designation from the FDA for the use of its PhageBank™ (a continually expanding library of phages) to treat prosthetic joint infections. APT will now be eligible for seven years of

The FDA has authorized Armata Pharmaceuticals to initiate a phase 1b/2a clinical trial, which they are calling "SWARM-P.a.", to test AP-PA02, its lead phage cocktail candidate, against Pseudomonas aeruginosa airway infections in cystic fibr

Sensei Biotherapeutics has raised $28.5 million to advance their pipeline of personalized cancer drugs, one of which is an immunophage therapy that involves engineering lambda phage to display tumor-associated antigens, leading activated T

CARB-X is awarding the Indian phage biotech company GangaGen Biotechnologies up to $2.5 Million (with possibility of an additional $8.1 Million if milestones are met) to develop klebicins to treat Klebsiella pneumoniae.

Locus Biosciences signed a $144 million contract with BARDA to support phase II and III clinical trials of LBP-EC01, Locus' CRISPR phage (crPhage™) product.

Adaptive Phage Therapeutics was recognized as a 2020 Champion of Maryland Manufacturing for its efforts to provide emergency phage access to COVID-19 patients with secondary bacterial infections.

Micreos has initiated a clinical trial to evaluate a topically-applied phage endolysin as a therapy for Atopic Dermatitis.

The Central Institute of Brackishwater Aquaculture, an Indian research institute, has been developing phage cocktails for aquaculture. They've now transferred their phage technology to Salem Microbes Private Ltd, so it can be made available

DuPont Animal Nutrition announced a partnership with Proteon Pharmaceuticals toward development of phage technology for poultry producers.

BiomX, which customizes phages against microbiome disease-associated bacteria, has entered a collaboration with Boehringer Ingelheim. Their goal is to discover microbiome-based biomarkers for inflammatory bowel disease.

US phage therapy company Adaptive Phage Therapeutics has received a $9.8-million Department of Defense Award to develop phage-based vaccine candidates against SARS-CoV-2.

The Austrian phage therapy company PhagoMed has been selected as a Gold Track company (one of 5) by EIT Health, the premier biotech acceleration program in Europe.

The Mayo Clinic has invested $1.75 million in Adaptive Phage Therapeutics, which will allow APT to initiate a clinical trial to address periprosthetic joint infections (an estimated commercial market of $900 million per year). The trial is